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INTRODUCTION:
Plasma-derived or recombinant coagulation factors provide an important option for the prevention and treatment of bleeding episodes for patients with coagulation disorders, including hemophilia with or without inhibitors. 1 Although current treatment is efficacious, there are limitations prompting the research community to develop new therapeutics including protein, DNA/RNA, and gene-based approaches. Efforts centered on increasing protein activity or circulating half-life are most advanced and are in clinical development or have been just approved.
2-4
Recently, we took a different approach and used information about the allosteric control of coagulation serine proteases to stabilize factor Xa (FXa) in a zymogen-like state using mutagenesis. [5] [6] [7] FX circulates as a zymogen and is converted to the protease state following proteolysis at a highly conserved site (R 15 -I 16 ). 8, 9 Liberation of the new N-terminus (I 16 -VGG) drives a conformational change which leads to maturation of the catalytic domain which imparts function. [10] [11] [12] We generated a novel FXa variant (e.g. FXa-I16L) with zymogen-like properties which shows promise in bypassing deficiencies upstream of the common pathway such as hemophilia. FXa-I16L is rendered partially inactive due to a defect in transitioning from zymogen to the protease state. However, its biologic activity is fully rescued when bound to FVa. 5 Preclinical studies in hemophilic mice indicate that FXa-I16L appears to be safe and is highly efficacious after a single dose in multiple injury models. Further, it is ~20-50-fold more effective than recombinant FVIIa in these models. 6, 7 For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From
Ivanciu and Camire 4/17/15
Page 5
Although FXa-I16L corrects the cogulation defect in hemophilic mice, its half-life is relatively short (<15-30 min) which could limit its use as a prophylactic for the prevention of bleeds. Due to the general mechanism by which zymogens transition to the protease state, the full range of activity/half-life that could be achieved in this new class of FXa variants has yet to be fully explored. Based on our prior work, mutations at position 16 or 17 will impact function; yet the extent of the alteration with a given amino acid is not obvious and needs to be empirically determined. This altered function is defined as the enzyme's zymogenicity-the ratio of the activity of the mature protease to the activity of the zymogen. Like most serine proteases, FX/FXa has a large (>10,000-fold) zymogenicity suggesting it should be possible to generate variants with a wide range of activities which reflects, at least in part, a differential shift along the zymogen to protease transition pathway. Here we altered the zymogenicity of FXa and created a repertoire of variants with attractive properties for treatment of bleeding conditions.
For personal use only. . Normal human pooled plasma (NHP) and factor deficient plasmas were purchased from George King Biomedical, Inc. Automated activated partial thromboplastin time reagent (aPTT; TriniClot) was from Trinity Biotech.
Proteins. Recombinant wt-FXa and FVa were purified as described previously. 15, 16 Human prothrombin was isolated from plasma as described previously. 17 The FX activator from Russell's viper venom (RVV X-CP ) was purified as described before. 18 Molecular weights and extinction coefficients (E 0.1% 280 nm) of various proteins used were taken as previously reported. 6, 16 All functional assays were performed at 25°C in 20 mM Hepes, 0.15 M NaCl, 0.1% (w/v) PEG-8000, 2 mM CaCl 2 , pH 7.4 (assay buffer).
For personal use only. Plasma-based coagulation assays. Thrombin generation assays in human or mouse plasma were determined as described. 7, 19 The aPTT clotting assay was performed by a modified one-stage assay as described. 5 Data Analysis. Data were analyzed according to nonlinear least squares regression analysis.
Estimates of error represent plus or minus 2 standard deviations (SDs). The qualities of fits were assessed by criteria previously described. 23 Initial velocity measurements were analyzed by fitting data to the Henri-Michaelis-Menten equation to yield values for K m and V max . 24 The rate of inhibition of FXa by ATIII was measured under pseudo-first order rate conditions and the second-order rate constant was calculated by dividing the pseudo-order rate constant (k obs ) by the concentration of ATIII. 25 In vivo results are expressed as mean ± S.E.M. and analyzed using ANOVA followed by a Student-Newman-Keuls test. A P value <0.05 was considered statistically significant. 
RESULTS:
Expansion of zymogen-like FXa mutational framework. Previously we characterized a zymogen-like FXa variant (FXa-I16L) which proved safe and efficacious in bypassing the hemophilic phenotype. [5] [6] [7] New variants at position 16 or 17 (Table 1) were transiently transfected in HEK293 cells. We selected amino acids that were generally hydrophobic and slightly smaller or larger than Ile or Val. We also avoided charged amino acids as the new N-terminus inserts into a hydrophobic pocked following activation to FXa. After correction for antigen levels, activation with RVV-X cp yielded proteins that fell into three groups relative to wild-type (wt)-FXa. Select variants were chosen for characterization: "Group 1" (FXa-V17M; ~ 25% activity), "Group 2" (FXa-I16M, FXa-V17T; ~ 5% activity) and "Group 3" (FXa-V17S, FXa-I16T; <1-2% activity). SDS-PAGE showed the purified proteases exhibit the characteristic α -and β -forms of
FXa and γ-carboxyglutamic acid analysis yielded the expected results (data not shown).
Characterization of enzyme function. Maturation of the active site and stabilization of the oxyanion hole are hallmarks of the zymogen to protease transition. 9 Kinetic studies with the chromogenic substrate SpecXa (Table 2) or the active site FXa inhibitor Pefabloc tPA/Xa (Table   2 ) revealed that the variants have an impaired ability to bind these probes relative to wt-FXa.
The catalytic efficiency (k cat ) for SpecXa hydrolysis was also reduced to varying degrees. These data show that large differences in activity and substrate binding can be achieved depending on which amino acid is at position 16 or 17.
We and others have shown that the FVa binding site, active site and new N-terminus of FXa are allosterically linked. can thermodynamically rescue the activity of zymogen-like variants. 5, 6 Binding of the different FXa variants to SpecXa in the presence of saturating amounts of FVa-membranes was improved (Table 2 ). More compelling evidence comes from prothrombin activation experiments. When assembled into prothrombinase, Group 1 and 2 variants exhibit kinetic parameters that were similar to wt-FXa (Figure 1 ). Remarkably, even Group 3 variants (FXa-V17S and FXa-I16T) have second order rate constants for prothrombin activation that were within a factor of 5 despite exhibiting activity in the absence of FVa that was altered 100-1000-fold relative to wt-FXa ( Figure 1 ). Together these data show the remarkable and surprising ability of prothrombinase assembly to rescue FXa zymogen-like function.
Assessment of half-life and ATIII inhibition. Consistent with their altered zymogenicity, Group
3 variants exhibit the longest half-life (>350 min) in HB plasma, followed by Group 2 (>80 min)
and Group 1 variants (~10 min; Table 3 and Figure 2A ). Similar results were obtained using human HA plasma (data not shown) and mouse HB plasma ( Figure 2B ). ATIII, a serpin, which largely targets the active site of serine proteases, is considered one of the major physiologic inhibitors of FXa. 29 Consistent with extended half-lives, the variants have altered second order rate constants for inhibition by ATIII compared to wt-FXa (Table 2 ). These data show that the zymogen-like conformation protects the FXa variants from plasma inhibitors to varying degrees that correspond to their level of zymogenicity. This has a direct impact on their half-lives as the physiologic inhibitors largely dictate this parameter.
Assessment of zymogen-like variants in hemophilic plasma. Plasma-based assays were used to examine if the unique properties of the variants translate into a bypassing approach to mitigate Table 3 ). The most zymogenized variants (0.1 nM; FXa-V17S, FXa-I16T) had a modest but significant effect (Table 3) . Consistent with the idea that sub-optimal amounts of FVa are generated in situ during the clotting assay, saturating amounts of FVa (10 nM) added to the assay shortened the clotting times further (Table 3) .
Similarly, FXa variants added to the TGA in HB plasma yielded a robust thrombin signal with endogenous thrombin potential (ETP) and peak heights comparable to wt-FXa (Table 3 and Figure 3A ). Only FXa-I16T exhibited a markedly reduced thrombin generation profile. We speculate this reflects its significant zymogen-like character and the need for higher concentrations of FVa to rescue the variant. Consistent with this, the addition of FVa (20 nM)
yielded ~ 5-8-fold improvement in peak thrombin and ETP for FXa-I16T ( Figure 3B and Table   3 ). Since other zymogenic variants had robust TGA profiles, the addition of FVa had only a modest effect ( Figure 3B and Table 3 ). Similar results were obtained using human HA plasma (data not shown).
In vivo evaluation of zymogen-like FXa variants. Blood loss was monitored after a hemostatic challenge using HB mice on the Balb/c background. These experiments were conducted in two ways; protein was infused 2 min after injury ( Figure 4A ) or protein was infused prior to injury ( Figure 4B ). In either scenario, HB mice infused with PBS exhibit substantial blood loss (>200 μl) compared to hemostatically normal mice ( Figure 4 ). Infusion of Group 2 variants after injury significantly reduced blood loss ( Figure 4A ). Interestingly and perhaps counterintuitively, the The results were different when proteins were administered before injury. In a timed tail transection experiment, Group 3 variants were most effective especially when the proteins were given 15 or even 30 min prior to injury ( Figure 4B ). As expected, the Group 1 variant, FXa-V17M was essentially ineffective. The Group 2 variants were effective if administered 5 min before injury but exhibited decreasing efficacy if given 15 or 30 min before injury. Together these data suggest that when FXa variants are administered before injury, proteins with a long half-life and acceptable activity profile are most effective. Overall the data show that with the administration of a protease, the "activity" half-life and thus sensitivity towards circulating inhibitors contributes in a major way to efficacy and provides a short-term pro-hemostatic effect.
In addition to the tail transection model, injury to the carotid artery using FeCl 3 is useful to assess the efficacy of therapeutic procoagulants. As shown previously, 7,22 HB mice do not generally form an occlusive thrombus in this model. Following application of FeCl 3 (7.5%) to the carotid artery, hemostatically normal mice display full vessel occlusion within 15 min (Table   4 ). Administration of zymogen-like variants (450 μg/kg) 10 min after injury led to rapid and complete occlusion (< 3 min) in nearly all mice (Table 4 ). Due to its short half-life in mouse plasma (<20 sec; see Figure 2B ), wt-FXa was ineffective. When proteins were administrated 15
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Page 14 min prior to injury, FXa-V17M and FXa-I16M variants had poor efficacy while FXa-I16T was highly effective yielding complete vessel occlusion in 8 out of 9 mice (Table 4) . I16T . Based on the low activity of FXa-I16T, we were surprised that FVa could nearly rescue its function with respect to prothrombin activation.
Expanded characterization of FXa
Additionally, the variant is highly efficacious in both injury models especially when given prior to injury. In plasma, FXa-I16T has a half-life of well over 6-7 hr. (Table 3 ). These data suggest that FXa-I16T may be ideally suited for prophylaxis situations or to prevent bleeding.
The efficacy and safety of FXa-I16T was examined in additional experiments. HB mice were treated with the variant (450 μg/kg) and blood was collected at various times (10, 30, 60 and 120 min) after protein injection. As shown in Figure 5A and Supplemental Together, these data show that despite the poor activity of FXa-I16T it is effective at restoring thrombin generation and can do so even when given up to 1 hr prior to blood collection.
In addition to restoring thrombin generation, FXa-I16T dose-dependently reduced total blood loss in HB mice. When given 5 min prior to injury the protein showed statistically significant results at 28 µg/kg and normalized blood loss at 450 µg/kg ( Figure 6 ). There was a modest but statistically significant change in total blood loss when FXa-I16T was co-administered with FVa (400 µg/kg) versus the variant alone (p < 0.05; 28 or 56 µg/kg), suggesting that excess FVa can improve efficacy. No significant change in total blood loss was found when HB mice were infused with only FVa (400 µg/kg). In addition to the tail transection model, FXa-I16T showed a dose-dependent response in the FeCl 3 -injury model (Table 4) . Together, these data show that FXa-I16T is highly efficacious and appears to be ideally suited for the prevention of bleeding due to its suitable activity and long half-life.
We next monitored whether FXa-I16T is associated with an increase in markers of activation of coagulation. Following administration of 450 µg/kg FXa-I16T, no significant change in platelets counts or D-dimer levels were detected in HB mice over a 24 hr. period ( Figure 7A and 7B).
Similar results were obtained using range of doses (28 -225 µg/kg; n = 6-7; data not shown).
Infusion of FXa-I16T at the highest dose (450 µg/kg) exhibited a transient increase in TAT levels at 10 min, which normalized to baseline within 1 hr. (Figure 7C ). No change in TAT levels was observed in HB mice injected with lower therapeutic doses of the variant (28-225 µg/kg; Figure 7D ). Furthermore, there was no statistically significant difference in coagulation markers following infusion FXa-I16T (450 µg/kg) once daily for three consecutive days (data not shown). Together the bypassing approaches either directly enhance FXa production or dampen it by blocking inhibitory pathways. In principle, a more straightforward approach would be to provide FXa directly. Due to properties inherent to wt-FXa, which are too difficult to overcome, it cannot be used as a bypass product. 33, 34 As shown in the current study, altering FXa to a zymogen-like state circumvents several roadblocks and yields pro-hemostatic agents that are remarkably effective at enhancing thrombin generation at sites of vascular injury. Overall this strategy paradoxically diminishes rather than enhances enzyme function by shuttling the enzyme to a zymogen-like state. This, in general, is not an obvious first approach to bioengineering proteins as gains in enzyme activity are generally Another key aspect of the FXa variants is that they could be rescued via incorporation into the prothrombinase complex. Based on our prior studies, [5] [6] [7] this is due to FVa preferentially binding the protease conformation of the protein and altering the equilibrium between zymogen and protease. In the models employed, enough FVa derived from plasma or platelet stores must be available at the injury site to turn on the variants. In the absence of FVa, the variants have low activity and are at least partially resistant to circulating inhibitors such at ATIII. activation. As a result, the variant was effective at alleviating the hemophilic phenotype in mice when given up to an hour prior to injury.
An important finding from the current work is that certain variants performed much better than others depending on when the proteins were administered. By overcoming the endogenous inhibitors and imparting a prolonged half-life, the lower activity zymogen-like variants were particularly effective when infused prior to injury. Variants with moderate activity apparently have the right mix of activity/half-life so that they are most effective when used in the acute setting. Together these findings are important as they highlight that it is unlikely that one type of hemostatic agent will be effective in treating or preventing all types of clinical bleeding. Thus in situations where re-bleeding occurs, the therapeutic intervention would need a suitable half-life to retain hemostatic potency long enough to address the injury. However, if there is an active bleed, a procoagulant hemostatic that is more potent and faster acting, but eliminated quickly, may be more effective and safe.
We also show that the variants are safe as measured by changes in markers of coagulation. 7 Following administration of the variants, platelets, D-dimer, and fibrinogen levels were unchanged. Only at the highest dose (450 μg/kg) of FXa-I16T, TAT levels transiently increased but quickly returned to baseline. These data likely reflect the low activity of the variants towards physiologic substrates in the absence of circulating FVa. While these studies are done in mice they are important as the possibility of systemic activation of coagulation is a major concern with any procoagulant therapy. Another area of concern not investigated here is the potential immunogenicity of the variants. While the complexity of the immune system makes predictions very difficult, an antibody response to a particular zymogen-like FXa variant could be mounted.
Clearly these studies are difficult to do in animals with any predictive value even if speciesspecific proteins are used. Nevertheless, a recent phase III clinical trial with a FVIIa variant suggest that the immune response to a mutant protein must be taken very seriously. 35 In summary, we exploited the FX zymogen to protease transition and identified a series of variants with a range of activities and half-lives which are effective for the treatment of hemophilia. The in vivo data show the physiologic circulating inhibitors provide a steep barrier to overcome as they rapidly neutralize the most active of the zymogen-like variants. However, through mutagenesis the right balance of activity and half-life can be attained and depending on the timing of administration and potentially the type of injury, a highly efficacious bypass agent can be identified. Still, the data show that the most zymogen-like variant can evade interactions with inhibitors best and attain a prolonged half-life and thus would be most effective in situations in which the molecule is administered prior to injury. The shorter half-life but more potent FXa variants were most effective to stop acute bleeding. In fact, in this situation, a short half-life could be beneficial from a safety standpoint. We conclude that zymogen-like FXa variants are robust procoagulant hemostatic agents that, due to their mechanism of action, could be used for a range of bleeding situations not just restricted to hemophilia. FXa-V17S 1100 ± 130 41 ± 8.5 -40 ± 4 FXa-I16T 500 ± 63 5.3 ± 0.38 -70 ± 9 a Kinetic parameters for free Xa or prothrombinase were determined from initial velocity studies conducted with SpecXa or S-2238; b Inhibition kinetics of free Xa were determined from initial velocity studies with SpecXa or S-2765. The errors in the fitted constants represent ± 2 SDs for each variant. The data are representative of 2-3 independent measurements. ND = No determined. Description of the experimental design and reactant concentrations can be found under "Supplemental Methods" . 
